What is it about?
Several new targeted drugs have recently been approved for the treatment of breast cancer [1]. Despite continuing progress in research and clinical practice, therapeutic resistance and relapse rates remain high in advanced disease [2]. We summarize the latest developments in genome analysis and translational therapeutic implications.
Featured Image
Why is it important?
An evidence-based strategy is essential to validate promising breast cancer genome analysis in time and space
Perspectives
The innovative identification of intratumor heterogeneity and circulating genomic subclones as biomarkers for tailored treatment is highly promising, but still, validation is required. The vast majority of available genomic studies is limited by small sample size, high heterogeneity of baseline clinical and TNM-staging data and the lack of a strict protocol for accurate detection of spatiotemporally evolving, ‘resistant’ genomic subclones. Further progress and refinement of integrated NGS systems, such as cfDNA-NGS and single-cell genome and/or RNA sequencing, could enable crucial translational implications.
Dr Demosthenes E. Ziogas
Peripheral General Hospital of Ioannina - Xatzikosta
Read the Original
This page is a summary of: Precise predictive and therapeutic strategy for breast cancer, Future Oncology, May 2018, Future Medicine,
DOI: 10.2217/fon-2018-0277.
You can read the full text:
Contributors
The following have contributed to this page
